Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03257033 · ClinicalTrials.gov registry record · Phase 3
Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC
A Phase 3 study of Locally Advanced Pancreatic Cancer, sponsored by RenovoRx.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 190
- Enrollment target
- 20
- Study locations
NCT03257033: Recruiting Phase 3 study of Locally Advanced Pancreatic Cancer, sponsored by RenovoRx.
NCT03257033 is a Phase 3 study of Locally Advanced Pancreatic Cancer that is actively recruiting participants, run by RenovoRx. The registered enrollment target is 190 participants, above the 58-participant average among 3 other Locally Advanced Pancreatic Cancer trials with a reported enrollment target (228% higher). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03257033, a Phase 3 study of Locally Advanced Pancreatic Cancer, is actively recruiting participants, sponsored by RenovoRx.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 190 participants
- Enrollment target
- 20
- Study locations
Study Summary
The study is a multi-center, open-label, randomized active controlled study of subjects with locally advanced pancreatic adenocarcinoma which is unresectable.
Primary Outcome
OS from time of randomization will be calculated using the Kaplan-Meier method and compared between the test and control groups using the stratified Wilcoxin Test
Conditions Studied
Interventions
- DRUG Gemcitabine
- DRUG nab-paclitaxel
- DEVICE RenovoCath
Study Locations (20)
Florida
- 21st Century Oncology - Fort Myers
- Miami Cancer Center - Miami
- Sarasota Memorial Health Care System - Sarasota
- Moffitt Cancer Center - Tampa
- ASCLEPES Research Centers - Weeki Wachee
California
- VA Loma Linda Healthcare System - Loma Linda
- Sutter Cancer Center Sacramento - Sacramento
Colorado
- Rocky Mountain Cancer Centers - Denver
- Comprehensive Cancer Care and Research Institute of Colorado, CCCRIC - Englewood
District of Columbia
- Sibley Memorial Hospital - a member of Johns Hopkins medicine - Washington D.C.
- Georgetown University - Washington D.C.
Louisiana
- Ochsner Clinic Foundation - New Orleans
- LSU Health Shreveport - Shreveport
New Jersey
- MD Anderson Cancer Center at Cooper Hospital - Camden
- Atlantic Health System - Morristown Medical Center - Morristown
Georgia
- Piedmont-Columbus Regional - John B. Amos Cancer Center - Columbus
Iowa
- University of Iowa Hospitals and Clinics - Holden Comprehensive Cancer Center - Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 190 participants |
| Start Date | 2018-03-12 |
| Est. Completion | 2026-09 |
| Phase | Phase 3 |
What NCT03257033 shows while recruiting
NCT03257033 is an interventional study that assigns participants to a tested intervention. The registered 190 participants enrollment target is mid-sized for trials with a published cap, above the 58-participant average among 3 other Locally Advanced Pancreatic Cancer trials with a reported enrollment target (228% higher).
The record links to 1 condition, with Locally Advanced Pancreatic Cancer appearing as the primary indexed condition, and to 3 interventions - of which Gemcitabine is the first listed.
NCT03257033 names 20 study sites across 11 states, led by Florida, California, Colorado.
Frequently Asked Questions
What is clinical trial NCT03257033 about?
NCT03257033 is a clinical study titled "Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC". The study is a multi-center, open-label, randomized active controlled study of subjects with locally advanced pancreatic adenocarcinoma which is unresectable.
What is the current status of trial NCT03257033?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 190 participants. The study started on 2018-03-12. Estimated completion is 2026-09.
What conditions does trial NCT03257033 study?
This clinical trial studies the following conditions: Locally Advanced Pancreatic Cancer.
What interventions are being tested in trial NCT03257033?
The interventions under investigation include: Gemcitabine (DRUG), nab-paclitaxel (DRUG), RenovoCath (DEVICE).
Who is sponsoring clinical trial NCT03257033?
This trial is sponsored by RenovoRx, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03257033 being conducted?
This trial has 20 study locations across California, Colorado, District of Columbia, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Locally Advanced Pancreatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors
RECRUITING · Phase 2
-
MicroEnvironment Tumor Effects of Radiotherapy - Comprehensive Radiobiology Assessment TRial
RECRUITING · NA
-
Phase I Nab-Paclitaxel Plus Gemcitabine With Proton Therapy for Locally Advanced Pancreatic Cancer (LAPC)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03642028 · 190 participants · Phase 4
Suvorexant: A Dual Orexin Receptor Antagonist for Treating Sleep Disturbance in Posttraumatic Stress
- NCT04015609 · 190 participants · NA
Psychotherapy Intervention for Latinos With Advanced Cancer
- NCT04284397 · 190 participants · Early Phase 1
Identification of Critical Thermal Environments for Aged Adults
- NCT04554914 · 190 participants · Phase 2
A Study to Evaluate Tabelecleucel in Participants With Epstein Barr Virus (EBV) Associated Diseases
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI